Clinical Trial Update: Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors [Phase 2]

View source ↗

Summary

Status update on a Phase 2 trial of nivolumab plus ipilimumab for advanced rare genitourinary tumors; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma
• Bladder Cancer
• Germ Cell Tumor
• Neuroendocrine Carcinoma
• Penile Cancer
• Prostate Cancer
• Small Cell Carcinoma
• Upper Tract Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Genitourinary Cancer, Adrenocortical Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING